{"id":"NCT01769170","sponsor":"Chimerix","briefTitle":"A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients","officialTitle":"A Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08","primaryCompletion":"2015-12","completion":"2016-01","firstPosted":"2013-01-16","resultsPosted":"2021-01-05","lastUpdate":"2021-07-21"},"enrollment":452,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["CMV"],"interventions":[{"type":"DRUG","name":"Brincidofovir","otherNames":["BCV","CMX001","Hexadecyloxypropyl cidofovir","HDP-CDV"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Brincidofovir","type":"ACTIVE_COMPARATOR"}],"summary":"This randomized, double-blind, placebo-controlled, parallel group, multicenter study compared the effectiveness of oral brincidofovir (BCV) to placebo for the prevention of cytomegalovirus (CMV) infection in stem cell transplant patients who were CMV seropositive but negative for CMV viremia before starting treatment with BCV.","primaryOutcome":{"measure":"Number of Participants With Clinically Significant CMV Infection Through Week 24 Post-Transplant","timeFrame":"24 weeks","effectByArm":[{"arm":"Brincidofovir","deltaMin":155,"sd":null},{"arm":"Placebo","deltaMin":78,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":43,"countries":["United States","Belgium","Canada"]},"refs":{"pmids":["30292744"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":173,"n":303},"commonTop":["Diarrhoea","Acute graft versus host disease","Abdominal pain","Nausea","Vomiting"]}}